Loading…
Nautilus Biotechnology, Inc. is projected to rise to $1.27 by 2027, a +30% move from its current price of $0.977. NAUT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $0.9264 | $0.9782 | $1.03 | +0.13% |
| Aug 5 | $0.9069 | $0.9795 | $1.06 | +0.26% |
| Aug 6 | $0.8925 | $0.9807 | $1.08 | +0.38% |
| Aug 7 | $0.8807 | $0.982 | $1.09 | +0.51% |
| Aug 8 | $0.8706 | $0.9833 | $1.11 | +0.64% |
| Aug 9 | $0.8616 | $0.9845 | $1.12 | +0.77% |
| Aug 10 | $0.8535 | $0.9858 | $1.14 | +0.90% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8535 | $0.9858 | $1.14 | +0.90% |
| Week 2 | $0.8113 | $0.9946 | $1.22 | +1.80% |
| Week 3 | $0.782 | $1.00 | $1.29 | +2.72% |
| Week 4 | $0.7591 | $1.01 | $1.35 | +3.64% |
| Week 5 | $0.7403 | $1.02 | $1.41 | +4.57% |
| Week 6 | $0.7244 | $1.03 | $1.47 | +5.51% |
| Week 7 | $0.7105 | $1.04 | $1.52 | +6.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Nautilus Biotechnology, Inc. is a development stage life sciences company focused on quantifying and unlocking the complexity of the proteome in the United States. It develops the Nautilus Voyager Platform, an end-to-end solution comprising instruments, reagents, consumables, and software analysis.
The Nautilus Voyager instrument is a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples.
The company offers additional tools including single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has research collaboration agreements with Genentech, Buck Institute, Allen Institute, Cornell University, the Qatar Foundation, and the Michael J. Fox Foundation.
Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Nautilus Biotechnology, Inc. trades at $1.04 with a market cap of $132.16M and is ranked 4046 by market capitalization. The current price sits near a historically small float for this development stage life sciences company.
The forecast indicates a mixed near-term price path, with neutral momentum in 2026 and bullish signals emerging in several later years, including notable upside in 2040 and 2050.
Looking ahead, the 2026 forecast shows an avg price of $1.04 with a max of $1.72 and a 0 ROI, indicating a flat near term. The 2027 forecast turns more constructive with an avg of $1.31 and a max of $1.95 (ROI 26.3), and a bullish sentiment. By 2040, the avg is projected at $2.09 (ROI 101.3) and by 2050 at $3.48 (ROI 234.8), both bullish, suggesting meaningful long-run upside potential despite near-term volatility.
A major floor 94.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 141.6% above — a clean break opens room to run.
A major ceiling 304.3% above — clearing it would confirm fresh momentum.
Key NAUT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NAUT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.18 | Sell | $1.16 | Sell |
| MA 10 | $1.45 | Sell | $1.35 | Sell |
| MA 20 | $1.60 | Sell | $1.56 | Sell |
| MA 50 | $2.04 | Sell | $1.93 | Sell |
| MA 100 | $2.48 | Sell | $2.15 | Sell |
| MA 200 | $2.23 | Sell | $2.10 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 19.73 | Buy |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -192.70 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | -43.85 | Sell |
| Bollinger %B (20,2) | -0.06 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.41 | Sell |
| Awesome (5,34) | -0.63 | Sell |
| Ultimate (7,14,28) | 12.19 | Buy |
| Momentum (10) | -0.76 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 0.87 | Buy |
| ADX (14) | 34.44 | Sell |
| ATR (14) | 0.09 | Info |
The 30-day technical picture shows a neutral stance with a low RSI of 20. The stock trades below the SMA50 of $2.09 and the SMA200 of $2.23, indicating modest near-term weakness relative to short- and longer-term averages. Support is at $1.04 and resistance at $2.36, framing a relatively tight near-term range.
The 30-day price range spans from $0.7149 to $1.51, highlighting limited upside momentum over the last month while the overall sentiment remains NEUTRAL.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.977 | $0.977 | $1.61 | 0% | Neutral | |
| $0.9235 | $1.27 | $1.88 | +30% | Bullish | |
| $0.7632 | $1.11 | $1.76 | +14% | Neutral | |
| $0.8094 | $1.25 | $2.07 | +27% | Bullish | |
| $0.6669 | $1.08 | $1.86 | +10% | Neutral | |
| $0.5701 | $0.9613 | $1.72 | -2% | Neutral | |
| $0.6493 | $1.14 | $2.11 | +17% | Neutral | |
| $0.7172 | $1.31 | $2.50 | +34% | Bullish | |
| $0.8471 | $1.61 | $3.15 | +65% | Bullish | |
| $0.8248 | $1.63 | $3.26 | +67% | Bullish | |
| $0.8531 | $1.90 | $4.16 | +94% | Bullish | |
| $1.48 | $3.29 | $7.57 | +237% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.977 | $0.977 | $1.30 | +0.00% |
| September 2026 | $0.9176 | $1.12 | $1.42 | +14.22% |
| October 2026 | $0.8902 | $1.10 | $1.42 | -1.64% |
| November 2026 | $0.9037 | $1.13 | $1.48 | +2.68% |
| December 2026 | $0.9548 | $1.20 | $1.61 | +6.76% |
Click any year to see its month-by-month NAUT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, NAUT is projected to trade between $0.977 and $1.61, averaging $0.977 — a potential gain of 0% from today's $0.977. A consolidation phase looks the most probable path here.
Nautilus Biotechnology, Inc.'s 2027 outlook centres on $1.27, within a $0.9235 to $1.88 range. That is up +30% on the projected 2026 average. That marks a +30% change versus current levels. Momentum favours further upside here.
By 2028, NAUT could reach as high as $1.76, with a base case around $1.11 and support toward $0.7632 — roughly +14% from $0.977. A consolidation phase looks the most probable path here.
Expect NAUT to range from $0.8094 to $2.07 through 2029. The $1.25 average target implies a +27% move from current prices. That is up +12% on the projected 2028 average. Momentum favours further upside here.
The NAUT price prediction for 2030 points to an average of $1.08 (low $0.6669, high $1.86) — a potential gain of +10% on today's $0.977. A consolidation phase looks the most probable path here.
In 2031, NAUT is projected to trade between $0.5701 and $1.72, averaging $0.9613 — a potential decline of -2% from today's $0.977. That is -11% versus the projected 2030 average. Price action looks broadly range-bound.
Nautilus Biotechnology, Inc.'s 2032 outlook centres on $1.14, within a $0.6493 to $2.11 range. That is up +19% on the projected 2031 average. That marks a +17% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, NAUT could reach as high as $2.50, with a base case around $1.31 and support toward $0.7172 — roughly +34% from $0.977. Momentum favours further upside here.
Expect NAUT to range from $0.8471 to $3.15 through 2034. The $1.61 average target implies a +65% move from current prices. That is up +23% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The NAUT price prediction for 2035 points to an average of $1.63 (low $0.8248, high $3.26) — a potential gain of +67% on today's $0.977. Momentum favours further upside here.
In 2040, NAUT is projected to trade between $0.8531 and $4.16, averaging $1.90 — a potential gain of +94% from today's $0.977. That is up +16% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Nautilus Biotechnology, Inc.'s 2050 outlook centres on $3.29, within a $1.48 to $7.57 range. That is up +74% on the projected 2040 average. That marks a +237% change versus current levels. Momentum favours further upside here.
Investing $1,000 in NAUT today (≈ 1,023.541453 NAUT) could be worth
$3,368.47
+$2,368.47 (+237%) by 2050 · US Dollar
Based on the average projected NAUT price of $3.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NAUTwould be worth at today's price.
$1,000 invested in NAUT on Jul 31, 2025 (≈ 1,315.78949 NAUT) would be worth
$1,285.53
+$285.53 (+28.6%) today · 1.29× · US Dollar
Based on a NAUT entry price of $0.76 vs. today's $0.977.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.69 | $578.11 | -42.2% |
| 1 month ago | $1.84 | $530.98 | -46.9% |
| 3 months ago | $2.7 | $361.85 | -63.8% |
| 6 months ago | $2.01 | $486.07 | -51.4% |
| 1 year ago | $0.76 | $1,285.53 | +28.6% |
| All time (5.0y) ago | $7.49 | $130.44 | -87.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NAUT forecast.
Our base-case forecast reaches $2.00 around 2050.
Implied market cap at $2.00: $254.16M
The multi-year forecast paints a mixed but increasingly constructive long-run path. In 2030 the average price is projected at $1.10 with a 5.6 ROI and neutral sentiment, while by 2040 the average rises to $2.09 with a 101.3 ROI and bullish sentiment. In 2050 the average is forecast at $3.48 with a 234.8 ROI and bullish sentiment.
The sequence includes several bullish years such as 2033 (avg $1.42, ROI 36.7) and 2034 (avg $1.72, ROI 65.7), and a brief downturn in 2031 (avg $0.9948, ROI -4.3). These figures illustrate a potential trajectory toward higher price levels later in the decade and into the 2040s and 2050s, but remain subject to market volatility and the inherent uncertainty of price forecasts. Overall, the outlook signals meaningful upside in the longer term, with caution warranted given the occasional downside in intermediate years.
Tap a question to reveal the answer.
In 2030 the avg price is $1.10 with a min of $0.6804 and a max of $1.90, and ROI of 5.6; sentiment NEUTRAL.
Forecasts show mixed signals: neutral in 2026 (avg $1.04), bullish in 2027 (avg $1.31, ROI 26.3) and 2029 (avg $1.29, ROI 24.4), with bullish years in 2033 (avg $1.42, ROI 36.7), 2034 (avg $1.72, ROI 65.7), 2040 (avg $2.09, ROI 101.3), and 2050 (avg $3.48, ROI 234.8). Some years, such as 2031, show negative ROI (-4.3). These are forecasts and not guarantees.
The 2050 max forecast is $8.01, while the 2050 average is $3.48. Therefore, a price level of $5 is within the max scenario, though the average path does not imply a guaranteed move to $5.
Near-term indicators show sentiment NEUTRAL with RSI 20. Price sits below SMA50 ($2.09) and SMA200 ($2.23). Support is at $1.04 and resistance at $2.36. The 30-day price range is $0.7149 to $1.51.
Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Nautilus Biotechnology, Inc. Community Discussion
0Share your Nautilus Biotechnology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.